Oral PrEP in NYC and Long Island

A clinician may consider a rapid oral PrEP start after the required HIV assessment and product-specific safety review. A negative oral-fluid self-test or a booked appointment does not by itself exclude acute HIV or establish eligibility. Recent exposure within 72 hours may require PEP instead. Kidney function, hepatitis B, exposure route and the exact formulation affect the plan; do not start borrowed pills or stop current prevention on your own.

PrEP is medication for people without HIV who want to reduce their chance of acquiring it. A prevention visit helps choose a product that fits exposure, kidney health, other medicines and daily life. Options include daily oral emtricitabine/tenofovir and long-acting injections. The products have different eligibility and follow-up requirements. PrEP does not replace testing for other STIs, condoms when useful, or pregnancy prevention.

PrEP medicines act before infection becomes established. They work only when enough drug is present for the relevant exposure. Starting, stopping, missed doses and switching therefore need an agreed plan. Recent HIV exposure calls for a PEP assessment, because PrEP is not the emergency treatment course used after an exposure.

PrEP can be discussed with anyone who requests it, without having to disclose a particular identity or partner history. For oral PrEP, the indicated adult/adolescent weight threshold is 35 kg. Daily F/TDF, including generic Truvada, is used for sexual or injection-related risk in CDC guidance. Descovy, F/TAF, is for sexual risk excluding receptive vaginal sex; that limitation concerns the exposure, not simply someone’s gender identity. Injectable Apretude and Yeztugo are approved for sexual HIV prevention. Each requires confirmed HIV-negative status.

Discuss sexual and injection exposures, prior PrEP/PEP, recent missed doses and symptoms. If a potential HIV exposure was within 72 hours, get urgent PEP advice before a routine prevention appointment.

Oral PrEP requires kidney assessment and hepatitis B screening. CDC uses estimated creatinine clearance above 60 mL/min for F/TDF initiation and at least 30 mL/min for F/TAF. Descovy also involves lipid and weight monitoring. Injectables have their own HIV testing and interaction checks.

Agree on the first dose, when protection is expected for your exposure and what to use during a transition. An optional Apretude oral lead-in differs from Yeztugo’s required initiation tablets. Do not transfer one product’s schedule to another.

Oral prescriptions are connected to HIV testing at least every three months. Injection follow-up uses the relevant product calendar. Build in STI screening, refills, symptom contact and a backup plan for travel or coverage problems.

Follow-up assesses HIV status, adherence, exposure, side effects and ongoing preferences. Kidney testing occurs at intervals based on age, baseline function and other risks, with at least annual monitoring for oral PrEP. A missed dose does not have one universal answer across pills and injections. Contact the team if exposure occurred during an interruption, and do not wait for a later HIV test when PEP may still be timely.

CDC describes maximum protective drug levels after about seven days of daily oral PrEP for receptive anal sex and up to about 21 days for receptive vaginal sex and injection-drug exposure. Data are insufficient to assign the same onset for insertive sex. These are not an individual guarantee. Injections have their own initiation requirements and no universal immediate-protection promise; agree on additional prevention during a start or switch.

2-1-1 is an event-driven F/TDF approach. It is off-label and is not a CDC-recommended PrEP regimen, although some clinicians prescribe it for selected adult men who have sex with men. It is not a general schedule for adolescents, receptive vaginal exposure, Descovy or injections. Active hepatitis B and difficulty following a complex schedule can make it inappropriate. Obtain an individual plan rather than starting from an online dosing diagram.

Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.

Descovy combines emtricitabine and tenofovir alafenamide, which block HIV reverse transcriptase. Its PrEP indication is for HIV-negative adults and adolescents weighing at least 35 kg at risk through sex. It excludes receptive vaginal sex because effectiveness has not been evaluated for that exposure. The restriction concerns the exposure route, not simply gender. It can also be part of HIV treatment with other antiretrovirals under separate age, weight and regimen requirements. Descovy alone is not a complete treatment regimen. HIV testing, kidney assessment and hepatitis B review are part of choosing and monitoring it.

There is no fixed duration for every side effect or person. Diarrhea was the most common reported adverse reaction in the adult PrEP trial. Nausea was common in HIV-treatment trials. Ask the prescriber about persistent or worsening symptoms and whether they may have another cause. Kidney problems and other serious reactions need assessment rather than waiting for a supposed adjustment period. Seek urgent care for a severe allergic reaction. Do not stop or alter prevention without a plan. Stopping a tenofovir-containing product in someone with hepatitis B can worsen hepatitis and needs clinician monitoring.

Descovy alone is not a complete PEP regimen. CDC’s 2025 guidance includes dolutegravir plus tenofovir alafenamide or tenofovir disoproxil fumarate plus emtricitabine or lamivudine among preferred regimens for most adults and adolescents. A clinician may therefore use the emtricitabine/tenofovir alafenamide combination with another required drug when suitable. PEP use is off-label and differs from daily PrEP. Seek assessment promptly, ideally within 24 hours and no later than 72 hours after a qualifying exposure. The prescribed course lasts 28 days. Do not self-start leftover Descovy or wait for a routine PrEP appointment.

CDC describes oral PrEP reaching maximum drug levels associated with protection for receptive anal sex after about seven days of daily use. This is not a guarantee that an individual exposure is covered, and there are no established onset data for insertive anal or vaginal sex. Descovy is not indicated for receptive vaginal exposure. A timing estimate for another oral product does not remove that restriction. Ask your prescriber for the start plan and protection needed during the transition. A qualifying recent exposure within 72 hours needs PEP assessment. Starting ordinary PrEP afterward is not a substitute.

The labeled PrEP regimen for eligible adults and adolescents weighing at least 35 kg is one 200 mg/25 mg tablet daily, with or without food. Complete the required HIV assessment before starting and keep repeat HIV testing and kidney/hepatitis B care. Follow the prescription and ask the clinician or pharmacist what to do about a missed dose. Do not replace daily Descovy with a borrowed “2-1-1” schedule: that off-label approach concerns F/TDF, a different formulation. Descovy’s PrEP indication excludes receptive vaginal sex. Do not change or stop it without the prescribing clinician’s plan, especially with hepatitis B.

Ask a PrEP clinician to assess HIV status, exposure routes and whether Descovy fits your prevention needs. Descovy’s PrEP label excludes receptive vaginal sex. Bring recent test results, medicines, kidney and hepatitis B history, and tell the clinician about possible recent exposure or acute-HIV symptoms. HIV assessment must precede prescribing. Additional testing may be needed after an early negative result. Confirm the prescription, dispensing pharmacy, personal coverage and follow-up tests before assuming access is arranged. A qualifying exposure within 72 hours needs urgent PEP assessment rather than waiting for a routine prescription. FDA approval does not establish stock or prescribing availability at a particular Nao location.